LianBio
lianbio.comLianBio (NASDAQ: LIANY) is a clinical-stage biopharmaceutical company that in-licenses drug candidates from global partners for development and commercialization in China and other Asian markets. The company generates no product revenue, operating entirely on licensed assets while funding operations through equity raises. LianBio reported a net loss of $110.3 million for the year ended December 31, 2022, down from a net loss of $196.3 million for the year ended December 31, 2021. Research and development expenses were $59.8 million and general and administrative expenses were $65.6 million for the year ended December 31, 2022. The company had no revenue-generating products as of the filing date, with cash used in operating activities of $99.2 million in FY2022. LianBio operates under China's medical device and pharmaceutical regulatory framework, including oversight by the SAMR and relevant Medical Product Administrations.
Products & Services
LianBio holds in-licensed clinical-stage drug candidates targeting oncology indications. Clinical data disclosed in the filing references a program with a BICR-assessed objective response rate of 23.1% (95% CI: 15.6-32.2) in a full analysis set of 108 patients. No approved or commercialized products are identified in the filing excerpts.
Revenue Model
LianBio had no product revenue as of the 10-K filed March 28, 2023. Operations are funded through equity financing. Interest income of $4.3 million and other income of $10.4 million were recorded for the year ended December 31, 2022.
Customers & Markets
End markets are oncology patients in China and other Asian markets. No commercial customers or revenue-generating relationships are identified in the filing excerpts as of the year ended December 31, 2022.
Geographic Exposure
Operations are focused on China, with regulatory compliance obligations under Chinese authorities including the SAMR and Medical Product Administrations. Data storage and whistleblower systems involve servers in the United States, Mainland China, and Hong Kong.
Financial Snapshot
Loading...
